(Total Views: 177)
Posted On: 12/13/2017 7:58:46 AM
Post# of 72446
March 17 last patient visit concluded P2A
May 24 P2A Top-line announced
So I'm using nine weeks between conclusion announcement and top line.
The March 17 announcement sparked a run from ~$1.20 to ~$1.84 in the month following. So it could run a little this time though investors seem a bit fatigued here.
I feel that no matter what the results are, with the trials completed it will be deal making time. Even the most disappointing deal should still send us above $2 for the up list. It doesn't take much to move a $100M company if we partner into a phase 3 trial.
Bottom line is we need to get a deal and get onto the NASDAQ to get a fair valuation. To investors and patients...it's coming. Just hang in there.
Go IPIX!
May 24 P2A Top-line announced
So I'm using nine weeks between conclusion announcement and top line.
The March 17 announcement sparked a run from ~$1.20 to ~$1.84 in the month following. So it could run a little this time though investors seem a bit fatigued here.
I feel that no matter what the results are, with the trials completed it will be deal making time. Even the most disappointing deal should still send us above $2 for the up list. It doesn't take much to move a $100M company if we partner into a phase 3 trial.
Bottom line is we need to get a deal and get onto the NASDAQ to get a fair valuation. To investors and patients...it's coming. Just hang in there.
Go IPIX!
(1)
(0)
All my posts are my own personal opinion and speculation. They should not be used as the basis for any investment decision. No, I am not Scottsmith.
